Article
The FDA will review both Medicis Pharmaceutical Corp.'s Restylane and Inamed Corp's Hylaform on November 21.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
V-FC Handpiece Combines RF and Vacuum for Facial Contouring
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Acupuncture Reduces Frown Lines in Clinical Trial
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
POLL: Which Cosmeceuticals Are Most Popular, According to Social Media?
Icotrokinra Demonstrates Efficacy in Adolescents and Adults With Moderate to Severe Psoriasis in ICONIC-LEAD Phase 3 Study
Genetics Suggest New Vitiligo Treatment Path
Shawn Kwatra, MD, Endowed as Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine
Immunosuppressed Patients Respond Well to Electrochemotherapy for Skin Cancer
Nonsteroidal Tapinarof Cream Provides Long-Lasting AD Relief